Abstract
In a double-blind, placebo-controlled study, self-administered intranasal human interferon alpha A produced by recombinant DNA technology was given both before and after virus challenge with a respiratory coronavirus. The incidence of colds, the severity of symptoms and signs, and virus replication were all reduced in subjects receiving interferon as compared with those given placebo.
Dates
Type | When |
---|---|
Created | 13 years, 2 months ago (June 27, 2012, 8:03 p.m.) |
Deposited | 3 years, 6 months ago (Feb. 21, 2022, 9:28 a.m.) |
Indexed | 2 months, 3 weeks ago (June 11, 2025, 7:47 p.m.) |
Issued | 41 years, 10 months ago (Nov. 1, 1983) |
Published | 41 years, 10 months ago (Nov. 1, 1983) |
Published Print | 41 years, 10 months ago (Nov. 1, 1983) |
@article{Higgins_1983, title={Intranasal interferon as protection against experimental respiratory coronavirus infection in volunteers}, volume={24}, ISSN={1098-6596}, url={http://dx.doi.org/10.1128/aac.24.5.713}, DOI={10.1128/aac.24.5.713}, number={5}, journal={Antimicrobial Agents and Chemotherapy}, publisher={American Society for Microbiology}, author={Higgins, P G and Phillpotts, R J and Scott, G M and Wallace, J and Bernhardt, L L and Tyrrell, D A}, year={1983}, month=nov, pages={713–715} }